Leukemia and Lymphoma : Impact Factor & More
eISSN: 1029-2403pISSN: 1042-8194
Share this on:
Key Metrics
CiteScore 
4.2
Impact Factor
< 5
SNIP
0.79
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Leukemia and Lymphoma Journal Specifications
Indexed in the following public directories
Scopus 
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1989 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Leukemia and Lymphoma ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Leukemia and Lymphoma
Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction
- 28 Oct 2025
- Leukemia & Lymphoma
Germline predisposition to acute myeloid leukemia in polish patients
- 25 Oct 2025
- Leukemia & Lymphoma
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence
- 25 Oct 2025
- Leukemia & Lymphoma
Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML
- 23 Oct 2025
- Leukemia & Lymphoma
Risk stratification and early intervention in smoldering multiple myeloma
- 23 Oct 2025
- Leukemia & Lymphoma
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
- 21 Oct 2025
- Leukemia & Lymphoma
Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged ‘early’ after intensive induction
- 28 Oct 2025
- Leukemia & Lymphoma
Germline predisposition to acute myeloid leukemia in polish patients
- 25 Oct 2025
- Leukemia & Lymphoma
Prognostic relevance of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis and dose–response evidence
- 25 Oct 2025
- Leukemia & Lymphoma
Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML
- 23 Oct 2025
- Leukemia & Lymphoma
Risk stratification and early intervention in smoldering multiple myeloma
- 23 Oct 2025
- Leukemia & Lymphoma
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
- 21 Oct 2025
- Leukemia & Lymphoma
FAQs on Leukemia and Lymphoma
How long has Leukemia and Lymphoma been actively publishing? 
What is the publishing frequency of Leukemia and Lymphoma?
How many articles did Leukemia and Lymphoma publish last year?
What is the eISSN & pISSN for Leukemia and Lymphoma?
What is Citescore for Leukemia and Lymphoma?
What is SNIP score for Leukemia and Lymphoma?
Who is the publisher of Leukemia and Lymphoma?
